论文部分内容阅读
分别采用ＣＨＯＰ－ＶＰ１６方案对５２例和ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案对３０例非霍奇金淋巴瘤（ＮＨＬ）进行化疗，结果显示，ＣＨＯＰ－ＶＰ１６方案组的完全缓解率为５１．９％（２７／５２），总有效率为９２．３％（４８／５２）；ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案组的完全缓解率为４３．３％（１３／３０），总有效率为９０．０％（２７／３０）。两组的完全缓解率及总有效率比较，无显著性差异（Ｐ＞０．０５）。两组的主要毒副反应是骨髓抑制，ＣＨＯＰ－ＶＰ１６方案组和ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案组的白细胞下降（Ⅰ～Ⅲ度）分别为８２．７％（４３／５２）和８３．３％（２５／３０），但均无Ⅳ度下降发生，均无与毒性有关的死亡发生。结果表明，ＣＨＯＰ－ＶＰ１６方案治疗ＮＨＬ可以达到ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案相近的疗效，且使用方便，毒副反应较轻，可作为治疗ＮＨＬ的一线方案
CHOP-VP16 protocol was used to treat 52 cases of non-Hodgkin’s lymphoma (NHL) with 52 cases and ProMACE-CytaBOM regimen. The results showed that the complete remission rate of CHOP-VP16 regimen group was 51.9% (27/52) The total effective rate was 92.3% (48/52); the complete remission rate of the ProMACE-CytaBOM protocol group was 43.3% (13/30), and the total effective rate was 90.0% (27/30). There was no significant difference in complete remission rate and total effective rate between the two groups (P>0.05). The main toxicities and side effects of the two groups were myelosuppression. The leukopenia (I to III degree) in the CHOP-VP16 protocol group and the ProMACE-CytaBOM protocol group were 82.7% (43/52) and 83.3%, respectively (25/ 30) However, none of the IV-degree drops occurred, and no toxicity-related death occurred. The results show that the CHOP-VP16 regimen can achieve similar therapeutic effect with the ProMACE-CytaBOM regimen in the treatment of NHL, and it is easy to use and has less side effects. It can be used as a first-line treatment for NHL.